Immunome, Inc. (IMNM)

Search for stocks, ETFs, and funds for a quick comparison or use the comparison tool for more options.

The chart shows the growth of an initial investment of $10,000 in Immunome, Inc., comparing it to the performance of the S&P 500 index or another benchmark. All prices have been adjusted for splits and dividends.

Immunome, Inc. (IMNM) has returned 1.82% so far this year and 224.96% over the past 12 months.

Based on dividend-adjusted daily data since Oct 2, 2020, IMNM's average daily return is +0.22%, while the average monthly return is +5.57%. At this rate, your investment would double in approximately 1.1 years.

Historically, 44% of months were positive and 56% were negative. The best month was Feb 2021 with a return of +172.4%, while the worst month was Dec 2022 at -48.9%. The longest winning streak lasted 5 consecutive months, and the longest losing streak was 7 months.

On a daily basis, IMNM closed higher 47% of trading days. The best single day was Feb 18, 2021 with a return of +75.6%, while the worst single day was Mar 7, 2022 at -20.7%.

Immunome, Inc. has an annualized alpha of 42.73%, beta of 1.47, and R² of 0.06 versus S&P 500 Index. Calculated based on daily prices since October 05, 2020.

• This stock captured 230.30% of S&P 500 Index gains and 194.46% of its losses — amplifying both gains and losses, but participating more in upside than downside.
• R² of 0.06 means this stock moves largely independently of S&P 500 Index — capture ratios reflect limited market correlation rather than active downside protection. Consider using a more representative benchmark.

IMNM ranks 95 for risk / return — in the top 95% of stocks on our site. This means strong returns relative to risk — exactly what professional investors look for. Well-suited for investors who want to maximize return per unit of risk.

The table below present risk-adjusted performance metrics for Immunome, Inc. (IMNM) and compare them to a chosen benchmark (S&P 500 Index).

The Drawdowns chart displays portfolio losses from any high point along the way. Drawdowns are calculated considering price movements and all distributions paid, if any.

The table below displays the maximum drawdowns of the Immunome, Inc.. A maximum drawdown is a measure of risk, indicating the largest reduction in portfolio value due to a series of losing trades.

The maximum drawdown for the Immunome, Inc. was 94.89%, occurring on Dec 30, 2022. The portfolio has not yet recovered.

The current Immunome, Inc. drawdown is 49.42%.

The chart below shows the rolling one-month volatility.

The chart below illustrates the trends in the financial health of Immunome, Inc. over time, highlighting three key metrics: Total Revenue, Earnings Before Interest and Taxes (EBIT), and Net Income.

The Valuation section provides an overview of how Immunome, Inc. is priced in the market compared to other companies in the Biotechnology industry. It includes key financial ratios that help investors assess whether the stock is undervalued or overvalued.